Formulary
A patient information leaflet should be supplied to every patient when a systemic corticosteroid is prescribed.
Steroid Treatment Cards should be issued where appropriate to support communication of the risks associated with treatment and to record details of the prescriber, drug, dosage, and duration of treatment.
Steroid Emergency Cards should be issued to patients with adrenal insufficiency and steroid dependence for whom missed doses, illness, or surgery puts them at risk of adrenal crisis.
For further detailed information see https://bnf.nice.org.uk/drugs/prednisolone/.
| Betamethasone soluble tablets |
|
Formulary
|
Soluble tablets 500micrograms |
 MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration |
|
| Dexamethasone |
|
Formulary
|
Tablets 500micrograms, 2mg |
|
MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration |
|
|
| Hydrocortisone tablets |
|
Formulary
|
Tablets 10mg, 20mg |
|
MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration |
|
|
| Prednisolone |
|
Formulary
|
Tablets 1mg, 5mg
|
|
MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration |
|
|
| Betamethasone injection |
|
Formulary
|
Injection 4mg/1mL |
|
MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration |
|
| Deflazacort |
|
Formulary
|
Should only be used for patients in whom oral prednisolone is not tolerated due to cushingoid side effects. |
|
| Hydrocortisone Alkindi® |
|
Formulary
|
Granules in capsules for opening 0.5mg, 1mg, 2mg For replacement therapy of adrenal insufficiency in children and adolescents (from birth to <18 years old) |
|
LSCMMG: Hydrocortisone capsules MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration |
|
|
| Hydrocortisone MR capsules Efmody |
|
Formulary
|
Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults. |
|
LSCMMG: Hydrocortisone modified-release hard capsules MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration |
|
|
| Hydrocortisone sodium phosphate Efcortesol® |
|
Formulary
|
Injection 100mg/1mL |
|
Addison's Disease Self Help Group: What to do in an emergency |
|
|
| Hydrocortisone sodium succinate Solu-Cortef® |
|
Formulary
|
Injection 100mg vial |
|
Addison’s Disease Self Help Group: What to do in an emergency |
|
|
Links
- Addison’s Disease Self Help Group: What to do in an emergency
- Addison's Disease Self Help Group: What to do in an emergency
- Addisons website of national resources
- AddisonsDisease.org
- BSPED: Adrenal Insufficiency Consensus Guidelines
- Cochrane: Oral versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis
- COVID-19 Therapeutic Alert - Dexamethasone in the treatment of COVID-19
- LSCMMG: Hydrocortisone capsules
- LSCMMG: Hydrocortisone modified-release hard capsules
- MHRA Drug Safety Update October 2017: Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows’ milk allergy
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- NHSE: National Patient Safety Alert – Steroid Emergency Card to support early recognition and treatment of adrenal crisis in adults
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE: Multiple Sclerosis; management in primary and secondary care.